{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-049549","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.301306+00:00","generated_at":"2026-05-29T04:45:32.661472+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Serina Therapeutics presents data showing POZ-lipid avoids anti-PEG immune response in animal model","bullets":["POZ-lipid did not induce IgM or IgG antibody responses after repeated administration in an animal model.","Standard PEG-lipids used in mRNA vaccines (Pfizer-BioNTech, Moderna) elicited robust IgM and IgG responses.","Anti-PEG responses are linked to hypersensitivity reactions including anaphylaxis; POZ-lipid may enable safer LNP formulations.","Randall Moreadith, MD, PhD, Chief Development Officer, presented at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-049549","json":"https://secwatch.observer/filing/0001493152-24-049549.json","markdown":"https://secwatch.observer/filing/0001493152-24-049549.md","text":"https://secwatch.observer/filing/0001493152-24-049549.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224049549/0001493152-24-049549-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000149315224049549/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:45:32.661472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}